<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01527123</url>
  </required_header>
  <id_info>
    <org_study_id>115959</org_study_id>
    <nct_id>NCT01527123</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics of Benzoic Acid and Hippuric Acid After Topical Administration of GSK2585823 in Japanese Subjects With Acne Vulgaris</brief_title>
  <official_title>A Study to Evaluate the Pharmacokinetics of Benzoic Acid and Hippuric Acid After Topical Administration of GSK2585823 in Japanese Subjects With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This is a Phase 1, single-center, open-label study to evaluate the pharmacokinetics of the
      BPO metabolites benzoic acid and hippuric acid with 7-day repeat application of GSK2585823 in
      subjects with acne vulgaris
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2012</start_date>
  <completion_date type="Actual">June 1, 2012</completion_date>
  <primary_completion_date type="Actual">June 1, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of plasma benzoic acid and hippuric acid pharmacokinetics between pre-application and post-application (7-days repeat) of GSK2585823</measure>
    <time_frame>Participants will be followed up to 7 days after the last application, an expected average of 15 days</time_frame>
    <description>Blood PK sampling time frame: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 9,12hours post-dose (Day 1 and Day 8). Parameters: Maximum observed concentration(Cmax),Time of occurrence of Cmax (tmax), Area under the concentration-time curve from time zero (pre-dose) extrapolated to last time (AUC0-last), Area under the concentration-time curve from time zero (pre-dose) to 12 hours of quantifiable concentration within a subject across all treatments (AUC0-12) and Terminal phase half-life (t1/2,) for both benzoic acid and hippuric acid, after multiple application of GSK2585823, if calculable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of urine benzoic acid and hippuric acid</measure>
    <time_frame>Participants will be followed up to 7 days after the last application, an expected average of 15 days</time_frame>
    <description>Urine PK sampling time frame:0-4, 4-8, 8-12 hours post-dose (Day 1 and Day 8). Parameters: Renal clearance (CLr), amount of elimination (Ae) and fraction of elimination (fe), if calculable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in vital signs, ECGs, clinical laboratory tests</measure>
    <time_frame>Day -1 - Day 15</time_frame>
    <description>Vital signs, ECGs, clinical laboratory tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Collection of adverse events</measure>
    <time_frame>Participants will be followed up to 7 days after the last application, an expected average of 15 days</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>GSK2585823</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>External Preparation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2585823</intervention_name>
    <description>CLDM1%/BPO3%</description>
    <arm_group_label>GSK2585823</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese male or female subjects between 20 and 45 years of age inclusive at the time
             of signing the informed consent. Rationale: It is considered as adult and the
             qualifying maximum age expected of subjects with acne vulgaris with good health.

          -  Diagnosis of acne vulgaris by a dermatologist. Other than acne vulgaris subject must
             be in good general condition as determined by a investigator, based on a medical
             evaluation including medical history, physical examination, laboratory tests and
             cardiac monitoring. Rationale: It is considered as adult and the qualifying maximum
             age expected of subjects with acne vulgaris with good health.

          -  Subjects must have, on the face at screening (physical examination of dermatologist):
             A minimum of 17 but not more than 60 inflammatory acne lesions (papules / pustules),
             including nasal lesions; and a minimum of 20 but not more than 150 non-inflammatory
             acne lesions (open / closed comedones), including nasal lesions. It is set to evaluate
             acne patients in the same degree of severity of Japanese Phase 3 study.

          -  A female subject is eligible to participate if she is of: Child-bearing potential and
             agrees to use one of the contraception methods listed in the protocol for an
             appropriate period of time (as determined by the product label or investigator) prior
             to the start of dosing to sufficiently minimize the risk of pregnancy at that point.
             Female subjects must agree to use contraception until the follow-up examination.
             Rationale: It is considered as adult and the qualifying maximum age expected of
             subjects with acne vulgaris with good health.

          -  Body weight greater than and equal to 50 kg and body mass index (BMI) within the range
             greater than and equal to18.5 to less than 29.0 kg/m2 at screening Rationale: It is
             considered as adult and the qualifying maximum age expected of subjects with acne
             vulgaris with good health.

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form. Rationale: It is included
             from an ethical viewpoint according to GCP.

          -  Single QTcB less than 450 msec; or QTc less than 480 msec in subjects with Bundle
             Branch Block. Rationale: It is considered as adult and the qualifying maximum age
             expected of subjects with acne vulgaris with good health.

          -  AST, ALT, alkaline phosphatase and total bilirubin les than and equal to ULN at
             screening. Rationale: It is considered as adult and the qualifying maximum age
             expected of subjects with acne vulgaris with good health.

        Exclusion criteria:

          -  Have a history or presence of regional enteritis, inflammatory bowel disease (e.g.,
             ulcerative colitis, pseudomembranous colitis, chronic diarrhea, antibiotic-associated
             colitis or bloody diarrhea) or similar symptoms. Rationale: It is considered necessary
             to secure subject's safety.

          -  Pregnant females as determined by positive urine hCG test at screening or lactating
             females. Rationale: It is considered necessary to secure subject's safety.

          -  Used any of the following agents on the face within the previous 2 weeks: Topical
             antibiotics (or systemic antibiotics); Topical anti-acne medications (e.g., BPO,
             azelaic acid, resorcinol, salicylates); Abradants, facials, or peels containing
             glycolic or other acids; Masks, washes or soaps containing BPO, sulfacetamide sodium,
             or salicylic acid; Non-mild facial cleansers (e.g., facial scrub, cleansers containing
             agents with anti-inflammatory action); Moisturizers that contain retinol, salicylic
             acid, or α- or β-hydroxy acids; Astringents and toner (Subjects are allowed to enroll
             in this study, if the subject has been on treatment for more than 2 consecutive weeks
             prior to start of investigational product use); Topical corticosteroids (Use of
             inhaled, intra-articular, or intra-lesional steroids other than for facial acne is
             acceptable); Facial procedure (such as chemical or laser peel, microdermabration, blue
             light treatment, etc.); Topical retinoids on the face Rationale: It is considered
             necessary to appropriately assess the safety and pharmacokinetics of GSK2585823 in the
             study.

          -  Used systemic retinoids within the previous 6 months. Rationale: It is considered
             necessary to appropriately assess the safety and pharmacokinetics of GSK2585823 in the
             study.

          -  Received treatment with estrogens, androgens, or anti-androgenic agents within the
             previous 12 weeks (Subjects who have been treated with the above agents for more than
             12 consecutive weeks prior to start of investigational product are allowed to enrol as
             long as they do not expect to change dose, drug, or discontinue use during the study).
             Rationale: It is considered necessary to appropriately assess the safety and
             pharmacokinetics of GSK2585823 in the study.

          -  Used any medication that in the opinion of the investigator may affect this clinical
             study or evaluation of the study. Rationale: It is considered necessary to
             appropriately assess the safety and pharmacokinetics of GSK2585823 in the study.

          -  Have a known hypersensitivity or have had previous allergic reaction to any of the
             components of the investigational product. Rationale: It is considered necessary to
             appropriately assess the safety and pharmacokinetics of GSK2585823 in the study.

          -  Used any investigational therapy within the previous 4 months, or plan to participate
             in another clinical study at the same time. Rationale: It is considered necessary to
             appropriately assess the safety and pharmacokinetics of GSK2585823 in the study.

          -  A positive test for syphilis, HBs antigen, HCV antibody, HIV antibody, HTLV-1 antibody
             at screening. Rationale: To secure the site staffs' safety.

          -  A positive drug screen at screening. Rationale: It is considered necessary to
             appropriately assess the safety and pharmacokinetics of GSK2585823 in the study.

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  Participated in Japanese clinical studies planned by GlaxoSmithKline K.K. in the
             development of investigational products for acne vulgaris. Rationale: To be
             incompatible with stopping criteria.

          -  Are currently abusing drugs or alcohol. Rationale: It is considered necessary to
             appropriately assess the safety and pharmacokinetics of GSK2585823 in the study and to
             avoid the double-count of subjects.

          -  Have a significant medical history of being immunocompromised. Rationale: It is
             considered necessary to secure subject's safety and to appropriately assess the safety
             and pharmacokinetics of GSK2585823 in the study.

          -  People as follows and the family members; Employees of GlaxoSmithKline, contract
             research organization (CRO) or site management organization (SMO); Investigators (or
             subinvestigators). Rationale: : It is considered necessary to secure subject's safety.

          -  The subject has donated a unit of blood &quot;&gt;400 mL&quot; within the previous 4 months or
             &quot;&gt;200 mL&quot; within the previous 1 month. Rationale: It is considered necessary to secure
             subject's safety. It is included from an ethical viewpoint.

          -  Painters or subjects working at the coating industry including automobile mechanic.
             Rationale: : It is considered necessary to secure subject's safety.

          -  Unwillingness or inability to follow the procedures outlined in the protocol.
             Rationale: It is considered necessary to appropriately assess the safety and
             pharmacokinetics of GSK2585823 in the study and to avoid the subject potentially has
             high level of blood concentration of benzoic acid.

          -  Subject is mentally or legally incapacitated. Rationale: It is considered necessary to
             appropriately assess the safety and pharmacokinetics of GSK2585823 in the study.

          -  Have other conditions that would put the subject at unacceptable risk for
             participation in the study. Rationale: It is considered necessary to appropriately
             assess the safety and pharmacokinetics of GSK2585823 in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>171-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/115959?search=study&amp;search_terms=115959#rs</url>
    <description>Results for study 115959 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2012</study_first_submitted>
  <study_first_submitted_qc>February 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2012</study_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GSK2585823, benzoic acid, hippuric acid, acne vulgaris, pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzoic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>115959</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115959</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115959</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115959</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115959</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115959</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

